進行性肝がんの世界市場レポート 2025年

進行性肝がん市場規模は、今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）14.8％で37億8,000万米ドルに成長します。予測期間中の成長は、肝臓がんの罹患率の上昇、ヘルスケア支出の増加、遺伝的疾患の有病率の増加、精密医療の採用率の上昇、スクリーニング検査や診断検査の利用拡大など、いくつかの要因に起因すると考えられます。この期間に予想される主な動向には、治療における人工知能の統合、革新的な薬剤や治療法の開発、研究開発活動の拡大、標的治療薬の進歩、個別化医療に対する需要の高まりなどがあります。

慢性肝炎感染症の有病率の増加は、今後の進行性肝がん市場の成長を牽引すると予想されます。慢性肝炎感染症は、6カ月以上続く持続的なウイルス感染症で、肝障害、肝硬変、さらには肝がんを引き起こす可能性があります。これらの感染症の増加は、不十分なスクリーニングやワクチン接種プログラム、治療アクセスの遅れなどの要因に影響されています。B型肝炎（HBV）およびC型肝炎（HCV）の慢性感染は、肝硬変および肝がんの最も一般的なタイプである肝細胞がん（HCC）の主な原因です。これらのウイルス感染は、時間の経過とともに肝臓の炎症、損傷、そして最終的にはがんを引き起こします。これらの感染症の発症率が高いままであるため、より多くの人が進行性肝がんを発症する危険にさらされています。例えば、2024年4月、世界保健機関（WHO）は、2022年にB型慢性肝炎が世界で2億5,400万人に感染し、毎年120万人が新たにB型肝炎と診断されたと報告しました。その結果、長期にわたる肝炎感染の蔓延が進行性肝がん市場の拡大に寄与しています。

進行性肝がん市場の主要企業は、治療効果を高め、副作用を軽減し、最終的に患者の予後を改善するために、ヒトモノクローナル抗体などの革新的な治療法の開発に注力しています。ヒトモノクローナル抗体は、有害な病原体やがん細胞と戦う免疫系の能力を模倣した実験室製の分子です。この分子は、有害な病原体やがん細胞の表面にある特定の抗原を標的とし、免疫反応を引き起こすことで機能します。例えば、2022年10月、米国に本社を置く製薬会社アストラゼネカは、米国食品医薬品局（FDA）が、切除不能な肝細胞がん（HCC）の成人患者の治療薬として、イムジュド（トレメリムマブ）とイムフィンジ（デュルバルマブ）の併用を承認したと発表しました。この承認は、HIMALAYA第III相臨床試験の結果に基づいており、この併用療法はソラフェニブに比べて死亡リスクを22％減少させました。さらに、この併用療法を受けた患者の約31％が3年後も生存していたのに対し、ソラフェニブ治療を受けた患者では20％でした。STRIDEとして知られるこの治療レジメンは、イムジュドを単回投与した後、イムフィンジを4週間ごとに定期投与するもので、治療選択肢が限られている患者に新たな治療選択肢を提供するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界進行性肝がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の進行性肝がん市場：成長率分析
• 世界の進行性肝がん市場の実績：規模と成長, 2019-2024
• 世界の進行性肝がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界進行性肝がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の進行性肝がん市場テストの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 画像検査
• 生検
• ゲノム検査
• その他のテストの種類
• 世界の進行性肝がん市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 蛍光in situハイブリダイゼーション
• 次世代シーケンシング
• 蛍光免疫測定
• 比較ゲノムハイブリダイゼーション
• 免疫組織化学
• その他のテクノロジー
• 世界の進行性肝がん市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 直接入札
• 小売売上高
• その他の流通チャネル
• 世界の進行性肝がん市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• スクリーニング
• 診断と予測
• 予後
• 調査
• 世界の進行性肝がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• がん研究センター
• 学術機関
• 診断センター
• 外来手術センター
• その他のエンドユーザー
• 世界の進行性肝がん市場画像検査の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 超音波
• CT（コンピュータ断層撮影）スキャン
• MRI（磁気共鳴画像）
• PET（陽電子放出断層撮影）スキャン
• 世界の進行性肝がん市場、生検の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 針生検
• 腹腔鏡下生検
• 外科的生検
• 世界の進行性肝がん市場ゲノム検査の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 次世代シーケンシング（NGS）
• PCR（ポリメラーゼ連鎖反応）検査
• 遺伝子変異プロファイリング
• 世界の進行性肝がん市場、その他のテストタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血清バイオマーカー検査
• 肝機能検査
• アルファフェトプロテイン（AFP）検査
• エラストグラフィー検査

第7章 地域別・国別分析

• 世界の進行性肝がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の進行性肝がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 進行性肝がん市場：競合情勢
• 進行性肝がん市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca plc
• Novartis AG
• Eli Lilly and Company
• Stryker Corporation
• Agilent Technologies Inc.
• Eisai Co. Ltd.
• Jiangsu Hengrui Pharmaceutical Co. Ltd
• Exelixis Inc.
• Sirtex Medical Limited
• Eureka Therapeutics
• Abbisko Therapeutics Co. Ltd.
• Binhui Biopharmaceutical Co. Ltd.
• Tempest Therapeutics Inc.
• Auransa Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 進行性肝がん市場2029：新たな機会を提供する国
• 進行性肝がん市場2029：新たな機会を提供するセグメント
• 進行性肝がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Advanced liver cancer, or hepatocellular carcinoma (HCC) in its later stages, refers to liver cancer that has either spread beyond the liver or grown large enough to significantly impair liver function. At this stage, the cancer may have invaded nearby blood vessels, lymph nodes, or other distant organs, complicating treatment. Common symptoms include jaundice, abdominal pain, weight loss, and fatigue.

Key diagnostic methods for advanced liver cancer include imaging tests, biopsies, genomic tests, and others. Imaging tests play a vital role in diagnosing, staging, and monitoring hepatocellular carcinoma (HCC) by offering detailed images of the liver and surrounding organs. These tests encompass a variety of technologies such as fluorescent in situ hybridization, next-generation sequencing, fluoroimmunoassay, comparative genomic hybridization, immunohistochemistry, and more. They are distributed through different channels, including direct tenders, retail sales, and others. These tests are used in several areas, including screening, diagnostics, prognostics, and research, and are employed by various end users, such as hospitals, cancer research centers, academic institutions, diagnostic centers, and ambulatory surgical centers.

The advanced liver cancer market research report is one of a series of new reports from The Business Research Company that provides advanced liver cancer market statistics including the advanced liver cancer industry global market size regional shares competitors with the advanced liver cancer market share detailed advanced liver cancer market segments market trends and opportunities and any further data you may need to thrive in the advanced liver cancer industry. This advanced liver cancer market research report delivers a complete perspective of everything you need with an in-depth analysis of the current and future scenarios of the industry.

The advanced liver cancer market size has grown rapidly in recent years. It will grow from $1.89 billion in 2024 to $2.17 billion in 2025 at a compound annual growth rate (CAGR) of 15.2%. The growth during the historic period can be attributed to several factors, including heightened awareness of liver cancer, a growing patient population, an increased demand for targeted therapies, the expansion of healthcare infrastructure, and a rising preference for minimally invasive treatments.

The advanced liver cancer market size is expected to see rapid growth in the next few years. It will grow to $3.78 billion in 2029 at a compound annual growth rate (CAGR) of 14.8%. The growth during the forecast period can be attributed to several factors, including the rising incidence of liver cancer, increased healthcare spending, the growing prevalence of genetic conditions, a higher adoption of precision medicine, and the expanding use of screening and diagnostic tests. Key trends expected during this period include the integration of artificial intelligence in treatments, the development of innovative drugs and therapies, expanding research and development activities, advancements in targeted therapeutics, and a growing demand for personalized medicine.

The increasing prevalence of chronic hepatitis infections is expected to drive the growth of the advanced liver cancer market in the future. Chronic hepatitis infections are persistent viral infections lasting over six months, which can cause liver damage, cirrhosis, or even liver cancer. The rise in these infections is influenced by factors such as insufficient screening and vaccination programs, as well as delayed treatment access. Hepatitis B (HBV) and hepatitis C (HCV) chronic infections are primary causes of liver cirrhosis and hepatocellular carcinoma (HCC), the most common type of liver cancer. Over time, these viral infections lead to liver inflammation, damage, and ultimately cancer. As the incidence of these infections remains high, more individuals are at risk of developing advanced liver cancer. For example, in April 2024, the World Health Organization (WHO) reported that, in 2022, chronic hepatitis B affected 254 million people globally, with 1.2 million new cases diagnosed each year. As a result, the growing prevalence of long-term hepatitis infections is contributing to the expansion of the advanced liver cancer market.

Leading companies in the advanced liver cancer market are focusing on the development of innovative treatments, such as human monoclonal antibodies, to enhance treatment effectiveness and reduce side effects, ultimately improving patient outcomes. A human monoclonal antibody is a laboratory-made molecule that mimics the immune system's ability to fight harmful pathogens or cancer cells. It works by targeting specific antigens on the surface of these harmful entities, triggering an immune response. For example, in October 2022, AstraZeneca, a pharmaceutical company based in the US, announced that the U.S. Food and Drug Administration (FDA) had approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) for treating adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. This approval followed the results of the HIMALAYA Phase III trial, which showed that the combination therapy reduced the risk of death by 22% compared to sorafenib. Additionally, about 31% of patients treated with the combination were alive after three years, compared to 20% of those treated with sorafenib. The treatment regimen, known as STRIDE, consists of a single dose of Imjudo followed by regular doses of Imfinzi every four weeks, offering a new therapeutic option for patients with limited treatment alternatives.

In March 2023, the University of Southern California (USC), a private research university based in the US, partnered with Auransa Inc. to further clinical trials for a new targeted treatment for liver cancer. This collaboration combines their expertise to enhance treatment effectiveness for liver cancer and other solid tumors. Auransa Inc., a pharmaceutical company based in the US, specializes in treating advanced liver cancers.

Major players in the advanced liver cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Stryker Corporation, Agilent Technologies Inc., Eisai Co. Ltd., Jiangsu Hengrui Pharmaceutical Co. Ltd, Exelixis Inc., Sirtex Medical Limited, Eureka Therapeutics, Abbisko Therapeutics Co. Ltd., Binhui Biopharmaceutical Co. Ltd., Tempest Therapeutics Inc., Auransa Inc., Mina Alpha Limited, Jennerex Inc.

North America was the largest region in the advanced liver cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in advanced liver cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the advanced liver cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The advanced liver cancer market consists of revenues earned by entities that provide services such as diagnostic services, surgical services, patient support and management. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced liver cancer market also includes sales of biopsy tools, computed tomography (CT) scans, liver function tests kit, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Advanced Liver Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on advanced liver cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for advanced liver cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The advanced liver cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Test Type: Imaging Test; Biopsy; Genomic Test; Other Test Types
• 2) By Technology: Fluorescent In Situ Hybridization; Next Generation Sequencing; Fluoroimmunoassay; Comparative Genomic Hybridization; Immunohistochemical; Other Technologies
• 3) By Distribution Channel: Direct Tenders; Retail Sales; Other Distribution Channel
• 4) By Application: Screening; Diagnostic And Predictive; Prognostic; Research
• 5) By End-User: Hospitals; Cancer Research Centers; Academic Institutes; Diagnostic Centers; Ambulatory Surgical Centers; Other End-Users
• Subsegments:
• 1) By Imaging Test: Ultrasound; CT (Computed Tomography) Scan; MRI (Magnetic Resonance Imaging); PET (Positron Emission Tomography) Scan
• 2) By Biopsy: Needle Biopsy; Laparoscopic Biopsy; Surgical Biopsy
• 3) By Genomic Test: Next-Generation Sequencing (NGS); PCR (Polymerase Chain Reaction) Testing; Genetic Mutation Profiling
• 4) By Other Test Types: Serum Biomarker Testing; Liver Function Tests; Alpha-Fetoprotein (AFP) Test; Elastography Tests
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck Co. Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Advanced Liver Cancer Market Characteristics

3. Advanced Liver Cancer Market Trends And Strategies

4. Advanced Liver Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Advanced Liver Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Advanced Liver Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Advanced Liver Cancer Market Growth Rate Analysis
• 5.4. Global Advanced Liver Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Advanced Liver Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Advanced Liver Cancer Total Addressable Market (TAM)

6. Advanced Liver Cancer Market Segmentation

• 6.1. Global Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Test
• Biopsy
• Genomic Test
• Other Test Types
• 6.2. Global Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluorescent In Situ Hybridization
• Next Generation Sequencing
• Fluoroimmunoassay
• Comparative Genomic Hybridization
• Immunohistochemical
• Other Technologies
• 6.3. Global Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Tenders
• Retail Sales
• Other Distribution Channel
• 6.4. Global Advanced Liver Cancer Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Screening
• Diagnostic And Predictive
• Prognostic
• Research
• 6.5. Global Advanced Liver Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Research Centers
• Academic Institutes
• Diagnostic Centers
• Ambulatory Surgical Centers
• Other End-Users
• 6.6. Global Advanced Liver Cancer Market, Sub-Segmentation Of Imaging Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ultrasound
• CT (Computed Tomography) Scan
• MRI (Magnetic Resonance Imaging)
• PET (Positron Emission Tomography) Scan
• 6.7. Global Advanced Liver Cancer Market, Sub-Segmentation Of Biopsy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Needle Biopsy
• Laparoscopic Biopsy
• Surgical Biopsy
• 6.8. Global Advanced Liver Cancer Market, Sub-Segmentation Of Genomic Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Next-Generation Sequencing (NGS)
• PCR (Polymerase Chain Reaction) Testing
• Genetic Mutation Profiling
• 6.9. Global Advanced Liver Cancer Market, Sub-Segmentation Of Other Test Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Serum Biomarker Testing
• Liver Function Tests
• Alpha-Fetoprotein (AFP) Test
• Elastography Tests

7. Advanced Liver Cancer Market Regional And Country Analysis

• 7.1. Global Advanced Liver Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Advanced Liver Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Advanced Liver Cancer Market

• 8.1. Asia-Pacific Advanced Liver Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Advanced Liver Cancer Market

• 9.1. China Advanced Liver Cancer Market Overview
• 9.2. China Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Advanced Liver Cancer Market

• 10.1. India Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Advanced Liver Cancer Market

• 11.1. Japan Advanced Liver Cancer Market Overview
• 11.2. Japan Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Advanced Liver Cancer Market

• 12.1. Australia Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Advanced Liver Cancer Market

• 13.1. Indonesia Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Advanced Liver Cancer Market

• 14.1. South Korea Advanced Liver Cancer Market Overview
• 14.2. South Korea Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Advanced Liver Cancer Market

• 15.1. Western Europe Advanced Liver Cancer Market Overview
• 15.2. Western Europe Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Advanced Liver Cancer Market

• 16.1. UK Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Advanced Liver Cancer Market

• 17.1. Germany Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Advanced Liver Cancer Market

• 18.1. France Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Advanced Liver Cancer Market

• 19.1. Italy Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Advanced Liver Cancer Market

• 20.1. Spain Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Advanced Liver Cancer Market

• 21.1. Eastern Europe Advanced Liver Cancer Market Overview
• 21.2. Eastern Europe Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Advanced Liver Cancer Market

• 22.1. Russia Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Advanced Liver Cancer Market

• 23.1. North America Advanced Liver Cancer Market Overview
• 23.2. North America Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Advanced Liver Cancer Market

• 24.1. USA Advanced Liver Cancer Market Overview
• 24.2. USA Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Advanced Liver Cancer Market

• 25.1. Canada Advanced Liver Cancer Market Overview
• 25.2. Canada Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Advanced Liver Cancer Market

• 26.1. South America Advanced Liver Cancer Market Overview
• 26.2. South America Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Advanced Liver Cancer Market

• 27.1. Brazil Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Advanced Liver Cancer Market

• 28.1. Middle East Advanced Liver Cancer Market Overview
• 28.2. Middle East Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Advanced Liver Cancer Market

• 29.1. Africa Advanced Liver Cancer Market Overview
• 29.2. Africa Advanced Liver Cancer Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Advanced Liver Cancer Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Advanced Liver Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Advanced Liver Cancer Market Competitive Landscape And Company Profiles

• 30.1. Advanced Liver Cancer Market Competitive Landscape
• 30.2. Advanced Liver Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Advanced Liver Cancer Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca plc
• 31.3. Novartis AG
• 31.4. Eli Lilly and Company
• 31.5. Stryker Corporation
• 31.6. Agilent Technologies Inc.
• 31.7. Eisai Co. Ltd.
• 31.8. Jiangsu Hengrui Pharmaceutical Co. Ltd
• 31.9. Exelixis Inc.
• 31.10. Sirtex Medical Limited
• 31.11. Eureka Therapeutics
• 31.12. Abbisko Therapeutics Co. Ltd.
• 31.13. Binhui Biopharmaceutical Co. Ltd.
• 31.14. Tempest Therapeutics Inc.
• 31.15. Auransa Inc.

32. Global Advanced Liver Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Advanced Liver Cancer Market

34. Recent Developments In The Advanced Liver Cancer Market

35. Advanced Liver Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Advanced Liver Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Advanced Liver Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Advanced Liver Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer